Infliximab in paediatric inflammatory bowel disease

被引：9

作者：

Vilar, Pere ^{[1
]}

Martin de Carpi, Javier ^{[1
]}

Acuna, Claudia E. ^{[2
]}

Luisa Masiques, Ma ^{[3
]}

机构：

[1] Hosp Univ St Joan Deu, Paediat Gastroenterol Sect, Barcelona 08950, Spain

[2] Hosp Gen Cataluna, Dept Paediat, Paediat Gastroenterol Unit, Barcelona, Spain

[3] Hosp Gen Granollers, Dept Paediat, Paediat Gastroenterol Unit, Barcelona, Spain

来源：

JOURNAL OF CROHNS & COLITIS | 2007年 / 1卷 / 01期

关键词：

Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Children; Infliximab; Growth;

D O I：

10.1016/j.crohns.2007.07.001

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Infliximab has been widely used in paediatric Crohn's disease, mainly in luminal and fistulous disease refractory to standard treatment and for extraintestinal manifestations. Moreover, there is growing experience with its use in refractory ulcerative colitis. Infliximab has shown similar efficacy and safety in children as in adult population. It is postulated that its early use in paediatric inflammatory bowel disease, as a bridging treatment until the onset of action of other immunomodulators, could reduce the use of steroids and change the natural history of the disease as well. The effect of infliximab on mucosal heating could also contribute to the normal growth and sexual maturation in these patients. (C) 2007 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

引用

页码：2 / 9

页数：8

共 60 条

[31] INSULIN-LIKE GROWTH-FACTORS AND THEIR BINDING-PROTEINS - BIOLOGICAL ACTIONS [J].

JONES, JI ;

CLEMMONS, DR .

ENDOCRINE REVIEWS, 1995, 16 (01) :3-34

[32] DECREASED HEIGHT VELOCITY IN CHILDREN AND ADOLESCENTS BEFORE THE DIAGNOSIS OF CROHNS-DISEASE [J].

KANOF, ME ;

LAKE, AM ;

BAYLESS, TM .

GASTROENTEROLOGY, 1988, 95 (06) :1523-1527

[33] PERMANENT GROWTH FAILURE IN PEDIATRIC INFLAMMATORY BOWEL-DISEASE [J].

KIRSCHNER, BS .

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1993, 16 (04) :368-369

[34] Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease [J].

Kolho, K-L ;

Ruuska, T. ;

Savilahti, E. .

ACTA PAEDIATRICA, 2007, 96 (01) :128-130

[35]

Kugathasan S, 2000, AM J GASTROENTEROL, V95, P3189

[36]

KUGATHASAN S, 2001, GASTROENTEROLOGY, V120, pA615

[37] Response to infliximab is related to disease duration in paediatric Crohn's disease [J].

Lionetti, P ;

Bronzini, F ;

Salvestrini, C ;

Bascietto, C ;

Canani, RB ;

Dé Angelis, GL ;

Guariso, G ;

Martelossi, S ;

Papadatou, B ;

Barabino, A .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (04) :425-431

[38] Infliximab in pediatric ulcerative colitis: Two-year follow-up [J].

Mamula, P ;

Markowitz, JE ;

Cohen, LJ ;

von Allmen, D ;

Baldassano, RN .

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2004, 38 (03) :298-301

[39] Inflammatory bowel disease in early childhood and adolescence: special considerations [J].

Mamula, P ;

Markowitz, JE ;

Baldassano, RN .

GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2003, 32 (03) :967-+

[40] Infliximab as a novel therapy for pediatric ulcerative colitis [J].

Mamula, P ;

Markowitz, JE ;

Brown, KA ;

Hurd, LB ;

Piccoli, DA ;

Baldassano, RN .

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2002, 34 (03) :307-311

← 1 2 3 4 5 6 →